HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants.

AbstractOBJECTIVE:
Nosocomial diarrhea is a major problem in pediatric hospitals worldwide. We evaluated the efficacy of orally administered Lactobacillus GG (LGG) in the prevention of this disease in young children.
STUDY DESIGN:
Eighty-one children aged 1 to 36 months who were hospitalized for reasons other than diarrhea were enrolled in a double-blind trial and randomly assigned at admission to receive LGG (n = 45) at a dose of 6 x 10(9) colony-forming units or a comparable placebo (n = 36) twice daily orally for the duration of their hospital stay.
RESULTS:
LGG reduced the risk of nosocomial diarrhea (> or =3 loose or watery stools/24 h) in comparison with placebo (6.7% vs 33.3%; relative risk: 0.2; [95% CI: 0.06-0.6]; number needed to treat: 4 [95% CI: 2-10]). The prevalence of rotavirus infection was similar in LGG and placebo groups (20% vs 27.8%, respectively; relative risk: 0.72; 95% CI: 0.33-1.56). However, the use of LGG compared with placebo significantly reduced the risk of rotavirus gastroenteritis (1/45 [2.2%] vs 6/36 [16.7%], respectively; relative risk: 0.13; 95% CI: 0.02-0.79; number needed to treat: 7; 95% CI: 3-40).
CONCLUSIONS:
Prophylactic use of LGG significantly reduced the risk of nosocomial diarrhea in infants, particularly nosocomial rotavirus gastroenteritis.
AuthorsH Szajewska, M Kotowska, J Z Mrukowicz, M Armańska, W Mikołajczyk
JournalThe Journal of pediatrics (J Pediatr) Vol. 138 Issue 3 Pg. 361-5 (Mar 2001) ISSN: 0022-3476 [Print] United States
PMID11241043 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Topics
  • Child, Preschool
  • Cross Infection (etiology, prevention & control)
  • Diarrhea, Infantile (etiology, prevention & control)
  • Double-Blind Method
  • Female
  • Humans
  • Infant
  • Lactobacillus
  • Male
  • Poland (epidemiology)
  • Prevalence
  • Probiotics (therapeutic use)
  • Risk
  • Rotavirus Infections (epidemiology, prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: